Our core team has more than 10 PHDS and more than 15 scientists with 10 years of work experience. The R&D and production center covers an area of more than 5,000 square meters, and the annual production capacity of antibodies is 180 kg. The main products are Adalimumab, alentuzumab, alistuzumab, alituzumab, bevacizumab, Cetuximab, Dalazumab, Denosumab, Dulaglutide, Eculizumab, Efmoroctocog alfa, Evolocumab, Infliximab, Ipilimumab, Mepolizumab, Natalizumab, Nivolumab, Omalizumab, Panitumumab, Pembrolimumab, Pertuzumab, Ramu cirumab, Rituximab, Secukinumab, Trastuzumab, Tocilizumab, Ustekinumab, Vedolizumab, etc. are listed in Annex 1.
We adhere to the business policy of "developing together with the needs of human health", and will research new technologies and develop new products according to the needs of customers. We will work together with friends from all walks of life to strive for a better future for human health.
Annex 1: Product list
|
No. |
Product Name |
Target |
CAS No. |
|
1 |
Pembrolimumab |
PD-1 |
1374853-91-4 |
|
2 |
Nivolumab |
PD-1 |
946414-94-4 |
|
3 |
Trastuzumab |
HER2 |
180288-69-1 |
|
4 |
Trastuzumab-Emtanisne |
HER2 |
1018448-65-1 |
|
5 |
Trastuzumab-Deruxtecan |
HER2 |
1826843-81-5 |
|
6 |
Aflibercept |
VEGFR |
862111-32-8 |
|
7 |
Cetuximab |
EGFR |
205923-56-4 |
|
8 |
Adalimumab |
TNF-α |
331731-18-1 |
|
9 |
Infliximab |
TNF-α |
170277-31-3 |
|
10 |
Bevacizumab |
VEGFR |
216974-75-3 |
|
11 |
Rituximab |
CD20 |
174722-31-7 |
|
12 |
Ipilimumab |
CTLA-4 |
477202-00-9 |
|
13 |
Vedolizumab |
Integrin α4β7 |
943609-66-3 |
|
14 |
Denosumab |
RANKL |
615258-40-7 |
|
15 |
Evolocumab |
PCSK-9 |
1256937-27-5 |
|
16 |
Alirocumab |
PCSK-9 |
1245916-14-6 |
|
17 |
Eculizumab |
Complement C5 |
219685-50-4 |
|
18 |
Ustekinumab |
IL-12、IL-23 |
815610-63-0 |
|
19 |
Omalizumab |
IgE |
242138-07-4 |
|
20 |
Ramucirumab |
VEGFR2 |
947687-13-0 |
|
21 |
Secukinumab |
IL-17 |
1229022-83-6 |
|
22 |
Daratumumab |
CD38 |
945721-28-8 |
|
23 |
Atezolizumab |
PD-L1 |
1380723-44-3 |
|
24 |
Dulaglutide |
GLP-1R |
923950-08-7 |
|
25 |
Tocilizumab |
IL-6R |
375823-41-9 |
|
26 |
Natalizumab |
Integrin α4 |
189261-10-7 |
|
27 |
Pertuzumab |
HER2 |
380610-27-5 |
|
28 |
Panitumumab |
EGFR |
339177-26-3 |
|
29 |
Mepolizumab |
IL-5 |
196078-29-2 |
|
30 |
Alemtuzumab |
CD52 |
216503-57-0 |
|
31 |
Efmoroctocog alfa |
Factor VIII |
1270012-79-7 |
